![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, January 18, 2018 7:24:57 PM
On as side note:
Halozyme (HALO) has effectively sold an exclusive license to BMY for it's Enhanze formulation that converts IV delivery of Opdivo to subcutaneous. This is a huge competitive advantage to BMY over MRK's Keytruda, because it's less expensive to administer, and insurance companies will favor Opdivo subcutaneous over Keytruda IV (assuming outcomes are similar).
What does this have to do with OncoSec?
If BMY or MRK approach OncoSec with an exclusive partnership deal for the EP IL-12, this could effectively lock out the competitor from marketing their product with EP IL-12. Would have to be an offer that OncoSec "can't refuse" in order for ONCS to sign an exclusive deal.
Things WILL get interesting, hopefully sooner rather than later.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM